The well researched narrative review by Bourke and colleagues1 offers a comprehensive overview of immune-related adverse events (irAEs) in cancer immunotherapy and their management. However, care needs to be taken in adopting too broad an approach, particularly in relation to dermatological irAEs.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Bourke JM, O’Sullivan M, Khattak MA. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust 2016; 205: 418-424. <MJA full text>
- 2. Hwang SJE, Anforth R, Carlos G, Fernandez-Penas P. Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr 2017; 108: 6-16.
- 3. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of antiprogrammed cell-death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74: 455-461.
- 4. Carlos GRM, Fernandez-Penas P, Uribe P. Rational use of topical corticosteroids. Aust Prescr 2013; 36: 159-161.
- 5. Sebaratnam DF, Murrell DF. Dermatology training and practice in Australia. Int J Dermatol 2014; 53: 1259-1264.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.